GHK-Cu
Copper Tripeptide-1 • Also called GHK CU, GHK Copper, Copper Peptide, Copper Peptide GHK-Cu
Injectable GHK-Cu is tracked separately from topical cosmetic use because the injectable form sits in a much riskier regulatory bucket.
Current status
Restricted
Skin and recovery-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Injectable formulations draw most of the regulatory concern and are the ones to watch for future status changes.
Primary Use
Skin and recovery-related interest
Also searched as
GHK CU, GHK Copper, Copper Peptide, Copper Peptide GHK-Cu
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Injectable use remains in the restricted compounding group..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when GHK-Cu status changes
State-specific notes
Ohio
Sterile compounding caution is elevated.
California
Compounding access is highly limited.